20.03.2023 08:48
Oculis AG, has completed the enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, corticosteroid for treating inflammation and pain following cataract surgery. The trial brings OCS-01 an important step further on the regulatory path to approval.